Clinical Trial VICCHEM1180


An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects with Primary Myelofibrosis, Post Essential Thrombocythemia-Myelofibrosis and Post Polycythemia Vera-Myelofibrosis Who Have Platelet Counts of 50 X10 9/L to 100 X10 9/L

Principal Investigator(s)

Sanjay Mohan


  • Protocol No. VICCHEM1180
  • Open Date: 01/04/2013
  • Staging: Phase II
  • Age Group: Adults
  • Scope: National
  • Objective: To determine the effects of Ruxolitinib on spleen volume and symptomatic burden in patients with Primary Myelofibrosis (PMF), Post Polycythemia Vera-Myelofibrosis (PPV-MF) and Post Essential Thrombocythemia-Myelofibrosis (PET-MF) who have Baseline platelet count of 50 x10^9/L to 100 x10^9/L.
  • Disease Sites: Hematologic
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Ruxolitinib
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01348490
  • Secondary Protocol No: INCB 18424-258



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.